![](https://endpts.com/wp-content/uploads/2022/11/Travis-Murdoch-HI-Bio-tile-1.jpg)
Travis Murdoch, HI-Bio CEO
ARCH-backed HI-Bio touts early data from two trials for rare kidney disease
A kidney-specific autoimmune disease with no approved therapies could face an opponent in felzartamab, an investigational monoclonal antibody, according to its developer.
Data from two …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.